Lung Cancer Screening Global Market Report 2025

Description

Lung cancer screening is a preventive strategy aimed at detecting cancer in the lungs at an early stage, often before any noticeable symptoms appear. It targets individuals at higher risk due to specific health or lifestyle factors. The goal of this process is to identify abnormal changes or growths in lung tissue early, improving the chances of effective treatment and reducing the overall impact of the disease.

The primary diagnostic methods for lung cancer screening include low-dose spiral computed tomography (CT) scans and chest X-rays. Low-dose spiral CT scans use reduced radiation to produce detailed cross-sectional images of the lungs, allowing early detection of lung abnormalities with high sensitivity. These scans are applied for different lung cancer types, including non-small cell lung cancer and small cell lung cancer, and across various age groups, such as individuals aged 50 and older or below 50. They are utilized by multiple end users, including hospitals, clinics, diagnostic centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The lung cancer screening market research report is one of a series of new reports from The Business Research Company that provides lung cancer screening market statistics, including the lung cancer screening industry global market size, regional shares, competitors with the lung cancer screening market share, detailed lung cancer screening market segments, market trends, and opportunities, and any further data you may need to thrive in the lung cancer screening industry. This lung cancer screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lung cancer screening market size has grown strongly in recent years. It will grow from $3.03 billion in 2024 to $3.33 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth during the historic period can be attributed to the rising prevalence of tobacco use, increasing awareness of early cancer detection, expansion of government initiatives and screening programs, a growing geriatric population, and greater penetration of private diagnostic centers.

The lung cancer screening market size is expected to see strong growth in the next few years. It will grow to $4.79 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth during the forecast period can be attributed to the increasing burden of air pollution and occupational exposures, rising clinical evidence supporting the benefits of early screening, expanding availability of insurance coverage, growing urbanization and lifestyle changes, and rising investments in radiology infrastructure. Key trends in this period include the integration of cloud-based imaging platforms, advancements in radiomics and image analytics, development of portable and point-of-care imaging devices, incorporation of decision support systems into radiology workflows, and progress in non-invasive biomarker-based screening.

The rising smoking rates are expected to drive growth in the lung cancer screening market. Smoking, the inhalation of smoke from burning substances, primarily tobacco has been increasing due to rising stress levels, with more individuals turning to smoking as a coping mechanism. Lung cancer screening helps address this trend by enabling early detection of smoking-related health risks, encouraging smoking cessation, and supporting public health initiatives to reduce tobacco use. For example, according to the Office for National Statistics in September 2023, around 4.5 million adults in Great Britain, or 8.7% of the population, reported using e-cigarettes either daily or occasionally in 2022, up from 7.7% in 2021. Therefore, the growing prevalence of smoking is fueling the lung cancer screening market.

Key players in the lung cancer screening market are focusing on innovations in artificial intelligence (AI) to improve early detection and diagnostic precision in chest imaging. Technologies such as normal flagging enhance diagnostic accuracy, reduce false positives, and help prioritize cases that require further review by automatically identifying scans with no abnormal findings. In May 2025, Lunit Inc., a South Korea-based medtech company, launched INSIGHT CXR4, its next-generation AI-powered chest X-ray analysis solution, now CE MDR-certified for use across Europe. This system assists radiologists by detecting 12 chest abnormalities including lung nodules, pneumonia, and acute bone fractures and incorporates features such as current-prior image comparison to support early disease detection and clinical decision-making.

In August 2022, Intelerad Medical Systems Inc., a U.S.-based medical imaging software provider, acquired PenRad Technologies, Inc. for an undisclosed sum. Through this acquisition, Intelerad aims to expand its offerings in mammography and lung cancer screening, improving workflow efficiency for radiologists and enhancing patient outcomes. PenRad Technologies Inc. specializes in lung cancer screening software, strengthening Intelerad's capabilities in advanced imaging solutions.

Major players in the lung cancer screening market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Abbott Laboratories Inc., Canon Inc., Medtronic Plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, and Delfi Diagnostics Inc.

North America was the largest region in the lung cancer screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lung cancer screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer screening market includes revenues earned by entities by providing services such as radiology interpretation, diagnostic follow-up procedures, patient risk assessment, and telehealth consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Screening Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer screening ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lung cancer screening market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan; Chest-X-Ray
2) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
3) By Age Group: 50 And Older; Below 50
4) By End-User: Hospitals And Clinics; Diagnostic Centers; Other End-Users
Subsegments:
1) By Low Dose Spiral Computed Tomography Scan: Screening; Diagnostic; Follow-Up
2) By Chest X-Ray: Posterior Anterior; Lateral; Portable
Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; AstraZeneca Plc; Abbott Laboratories Inc.; Canon Inc.; Medtronic Plc; Siemens Healthineers AG; Koninklijke Philips N.V.; GE Healthcare Technologies Inc.; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Shimadzu Corporation; NeoGenomics Laboratories Inc.; Freenome Holdings Inc.; Biodesix Inc.; Lunit Inc.; Infervision; Riverain Technologies; VisionGate; Delfi Diagnostics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37802

1. Executive Summary

2. Lung Cancer Screening Market Characteristics

3. Lung Cancer Screening Market Trends And Strategies

4. Lung Cancer Screening Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Lung Cancer Screening Growth Analysis And Strategic Analysis Framework

5.1. Global Lung Cancer Screening PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Lung Cancer Screening Market Growth Rate Analysis
5.4. Global Lung Cancer Screening Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Lung Cancer Screening Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Lung Cancer Screening Total Addressable Market (TAM)

6. Lung Cancer Screening Market Segmentation

6.1. Global Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Low Dose Spiral Computed Tomography Scan
Chest-X-Ray
6.2. Global Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer
6.3. Global Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
50 And Older
Below 50
6.4. Global Lung Cancer Screening Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Diagnostic Centers
Other End-Users
6.5. Global Lung Cancer Screening Market, Sub-Segmentation Of Low Dose Spiral Computed Tomography Scan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Screening
Diagnostic
Follow-Up
6.6. Global Lung Cancer Screening Market, Sub-Segmentation Of Chest X-Ray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Posterior Anterior
Lateral
Portable

7. Lung Cancer Screening Market Regional And Country Analysis

7.1. Global Lung Cancer Screening Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Lung Cancer Screening Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Screening Market

8.1. Asia-Pacific Lung Cancer Screening Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Screening Market

9.1. China Lung Cancer Screening Market Overview
9.2. China Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Screening Market

10.1. India Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Screening Market

11.1. Japan Lung Cancer Screening Market Overview
11.2. Japan Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Screening Market

12.1. Australia Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Screening Market

13.1. Indonesia Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Screening Market

14.1. South Korea Lung Cancer Screening Market Overview
14.2. South Korea Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Screening Market

15.1. Western Europe Lung Cancer Screening Market Overview
15.2. Western Europe Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Screening Market

16.1. UK Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Screening Market

17.1. Germany Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Screening Market

18.1. France Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Screening Market

19.1. Italy Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Screening Market

20.1. Spain Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Screening Market

21.1. Eastern Europe Lung Cancer Screening Market Overview
21.2. Eastern Europe Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Screening Market

22.1. Russia Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Screening Market

23.1. North America Lung Cancer Screening Market Overview
23.2. North America Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Screening Market

24.1. USA Lung Cancer Screening Market Overview
24.2. USA Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Screening Market

25.1. Canada Lung Cancer Screening Market Overview
25.2. Canada Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Screening Market

26.1. South America Lung Cancer Screening Market Overview
26.2. South America Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Screening Market

27.1. Brazil Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Screening Market

28.1. Middle East Lung Cancer Screening Market Overview
28.2. Middle East Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Screening Market

29.1. Africa Lung Cancer Screening Market Overview
29.2. Africa Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Screening Market Competitive Landscape And Company Profiles

30.1. Lung Cancer Screening Market Competitive Landscape
30.2. Lung Cancer Screening Market Company Profiles
- 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Canon Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Screening Market Other Major And Innovative Companies

31.1. Medtronic Plc
31.2. Siemens Healthineers AG
31.3. Koninklijke Philips N.V.
31.4. GE Healthcare Technologies Inc.
31.5. Quest Diagnostics Incorporated
31.6. Agilent Technologies Inc.
31.7. Shimadzu Corporation
31.8. NeoGenomics Laboratories Inc.
31.9. Freenome Holdings Inc.
31.10. Biodesix Inc.
31.11. Lunit Inc.
31.12. Infervision
31.13. Riverain Technologies
31.14. VisionGate
31.15. Delfi Diagnostics Inc.

32. Global Lung Cancer Screening Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Screening Market

34. Recent Developments In The Lung Cancer Screening Market

35. Lung Cancer Screening Market High Potential Countries, Segments and Strategies

35.1 Lung Cancer Screening Market In 2029 - Countries Offering Most New Opportunities
35.2 Lung Cancer Screening Market In 2029 - Segments Offering Most New Opportunities
35.3 Lung Cancer Screening Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer